Latest Stock Exchange Listings News

Cygnus Metals receives conditional TSX listing approval for Central Asia Metals shares amid unchanged positive expert opinion on the acquisition scheme.

Almonty Industries will voluntarily delist from the ASX by September 1, 2026, consolidating its trading on Nasdaq and Frankfurt amid strategic shifts in its market presence.

Sunrise Energy Metals has landed a conditional US$400 million loan commitment from the U.S. Department of War’s Office of Strategic Capital to back its Syerston Scandium Project, while also initiating plans for a U.S. securities listing.

Aldoro Resources has boosted the Kameelburg rare earth project’s Mineral Resource Estimate to 804.5 million tonnes, now hosting 1.37 million tonnes of contained NdPr oxide; exceeding key western-world deposits. The maiden Indicated Resource and robust metallurgical testwork set the stage for development.

Aldoro Resources has secured A$4.3 million through unsecured convertible notes, providing funding to accelerate development at its Kameelburg Critical Minerals Project and exploring a potential Hong Kong Stock Exchange listing.

Titomic Limited updates investors that its planned shift of corporate domicile from Australia to the US is still underway but the timeline has slipped, with a revised schedule expected by late July or August 2026.

Nova Minerals has secured New South Wales Supreme Court approval for its schemes of arrangement, paving the way for its US holding company to take control and triggering ASX delisting and NYSE admission.

Winsome Resources shareholders and optionholders overwhelmingly backed Li-FT Power’s takeover scheme, clearing a major hurdle before the Supreme Court’s final approval scheduled for 11 May 2026.

African Gold Ltd has finalised its court-approved scheme of arrangement, transferring all shares and options to Montage Gold Corp and preparing for imminent ASX delisting.

GCM Corporation finalises exclusive rights to its Very High Density technology, launches its first commercial heat sink products, and expands global prototyping efforts targeting high-growth sectors including EV infrastructure and data centres.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.